Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women. (APR)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by INC Research
Sponsor:
Collaborators:
AbbVie
Apotex Inc.
Aurobindo Pharma
Boehringer Ingelheim
Bristol-Myers Squibb
Cipla Ltd.
Hoffmann-La Roche
Gilead Sciences
Hetero Labs Ltd.
Janssen R&D Ireland
Lupin Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Mylan Laboratories
Novartis Pharmaceuticals
Pfizer
Prinston Pharmaceutical Inc.
Ranbaxy Inc.
Sandoz
Sciegen Pharmaceuticals Inc.
Sigmapharm Laboratories
Silarx Pharmaceuticals Inc
Strides Arcolab Ltd.
Teva Pharmaceuticals USA
ViiV Healthcare
Alvogen Korea
Amneal Pharmaceuticals, LLC
West-Ward Pharmaceuticals Corporation
Dr. Reddy's Laboratories UK Ltd.
Information provided by (Responsible Party):
INC Research
ClinicalTrials.gov Identifier:
NCT00404989
First received: November 27, 2006
Last updated: January 4, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2099
  Estimated Primary Completion Date: January 2099 (Final data collection date for primary outcome measure)